Skip to main content
Journal of Patient-Reported Outcomes
Fig. 3 | Journal of Patient-Reported Outcomes

Fig. 3

From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Fig. 3

CDF plot: change from baseline in SNOT-22 total score by overall VAS anchor. Overall VAS anchor groups were defined by change in overall VAS symptom score from baseline to Week 52: moderate to major improvement: ≤ − 4-point change in VAS score; minimal meaningful improvement: ≤ − 2 to > − 4-point change in VAS score; limited improvement or worsening (stable): > − 2 to < 2-point change in VAS score. CDF Cumulative distribution function, SNOT-22 Sino-nasal outcome test-22, VAS Visual analogue scale

Back to article page